Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)

Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past half century1 – CAL02 is a unique therapeutic agent that works differently from antibiotics,